Kancera AB (OSTO:KAN) Insider Ownership : 0.00 % (As of Dec. 12, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kancera AB's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kancera AB's Institutional Ownership is 0.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kancera AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Kancera AB Insider Ownership Historical Data

The historical data trend for Kancera AB's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Insider Ownership Chart

Kancera AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Get a 7-Day Free Trial

Kancera AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Kancera AB Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Kancera AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48

Website

http://www.kancera.com

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines